High HBsAb titers consistent across 3 lots of the trivalent HepB vaccine, Sci-B-Vac: Results from the second pivotal phase 3 double-blind, randomized controlled trial designed to assess the lot-to-lot consistency of Sci-B-Vac in adults (CONSTANT)

被引：0

作者：

Finn, Adam ^{[1
,2
]}

Vesikari, Timo ^{[3
]}

Van Damme, Pierre ^{[4
]}

Leroux-Roels, Isabel ^{[5
]}

Leroux-Roels, Geert ^{[5
]}

Segall, Nathan ^{[6
]}

Toma, Azhar ^{[7
]}

Garg, Naveen ^{[7
]}

Vallieres, Gerald ^{[7
]}

Aronson, Ronnie ^{[8
]}

Reich, Dennis ^{[9
]}

Sah, Hamilton ^{[10
]}

Arora, Samir ^{[11
]}

Ruane, Peter ^{[12
]}

Anderson, Corey ^{[13
]}

Cone, Clancy ^{[14
]}

Manns, Michael P. ^{[15
]}

Cosgrove, Catherine ^{[16
]}

Faust, Saul ^{[17
]}

Ramasamy, Maheshi ^{[18
,19
]}

Machluf, Nathalie ^{[20
]}

Spaans, Johanna ^{[20
]}

Yassin-Rajkumar, Bebi ^{[20
]}

Anderson, David ^{[20
]}

Popovic, Vlad ^{[20
]}

Diaz-Mitoma, Francisco ^{[20
]}

机构：

[1] Univ Bristol, Bristol, Avon, England

[2] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England

[3] Nordic Res Network Ltd, Oslo, Norway

[4] Univ Antwerp, Ctr Evaluat Vaccinat, Antwerp, Belgium

[5] Univ Ghent, Ghent, Belgium

[6] Clin Res Atlanta, Atlanta, GA USA

[7] Manna Res, Barrie, ON, Canada

[8] LMC Diabet & Endocrinol, Toronto, ON, Canada

[9] Medicor Res Inc, Pune, Maharashtra, India

[10] Care One, Ft Lee, NJ USA

[11] Aventiv Res, Columbus, OH USA

[12] Ruane Clin Res Grp Inc, Los Angeles, CA USA

[13] Clin Res Consortium, Las Vegas, NV USA

[14] Montana Med Res Inc, Missoula, MT USA

[15] Med Hsch, Hannover, Germany

[16] St Georges Univ Hosp, London, England

[17] NIHR Southampton Clin Res Facil, Southampton, Hants, England

[18] Churchill Hosp, Oxford Vaccine Grp, Ctr Clin Vaccinol & Trop Med, Oxford, England

[19] Univ Oxford, Oxford, England

[20] VBI Vaccines Inc, Cambridge, MA USA

来源：

JOURNAL OF HEPATOLOGY | 2020年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

AS169

引用

页码：S70 / S70

页数：1

共 3 条

[1] RAPID INCREASE IN ANTI-HBsAg TITERS AND HIGHER SEROPROTECTION RATES IN ADULTS IMMUNIZED WITH SCI-B-VAC COMPARED TO A MONOVALENT HEPATITIS B VACCINE: RESULTS FROM PROTECT - A DOUBLE-BLIND, RANDOMIZED, CONTROLLED, PHASE-3 STUDY
Langley, Joanne
Vesikari, Timo
Segall, Nathan
Ward, Brian J.
Cooper, Curtis
Poliquin, Guillaume
Smith, Bruce
Van Damme, Pierre
Leroux-Roels, Isabel
Leroux-Roels, Geert
Machluf, Nathalie
Spaans, Johanna
Yassin-Rajkumar, Bebi
Anderson, David E.
Popovic, Vladimir
Diaz-Mitoma, Francisco
HEPATOLOGY, 2019, 70 (06) : 1497A - 1497A
[2] Higher proportion of responders with hepatitis B antibody levels=100 miu/ml with the trivalent HepB vaccine, Sci-B-Vac, compared to Engerix-B: results from the phase 3 double-blind, randomized study comparing immunogenicity and safety (PROTECT)
Vesikari, Timo
Langley, Joanne
Segall, Nathan
Ward, Brian
Cooper, Curtis
Poliquin, Guillaume
Gantt, Soren
Smith, Bruce
Van Damme, Pierre
Leroux-Roels, Isabel
Leroux-Roels, Geert
Machluf, Nathalie
Spaans, Johanna
Yassin-Rajkumar, Bebi
Anderson, David
Popovic, Vlad
Diaz-Mitoma, Francisco
JOURNAL OF HEPATOLOGY, 2020, 73 : S579 - S579
[3] Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial
Diaz-Mitoma, Francisco
Popovic, Vlad
Spaans, Johanna N.
VACCINE, 2021, 39 (29) : 3892 - 3899

← 1 →